Hypertensive patients with atherosclerosis are known to be vulnerable to the worsening of existing cardiovascular problems. This study was undertaken to assure, whether the combination therapy of calcium channel blocker,Amlodipine (AMD), and HMG CoA reductase inhibitor, Atorvastatin (ATV), is effective in reducing atherosclerosis possibly by lowering lipid profile. Three⁽³⁾ groups of cardiovascular patients (n = 26), (both males and females; Age range 40 – 60 yrs) were selected. First and second groups were randomly given Amlodipine (10mg once daily), and Atorvastatin (40mg once daily) only, whereas combination of atorvastatin and amlodipine ( Dose 10/40 once daily) was given to third group for 45 days. Plasma lipid profile of three groups was evaluated at Day 0, 15 and 45. For the purpose of pre-clinical studies, muscle relaxant and stimulant activity was evaluated on 20 mice (swiss Webster). Significantly lowered values (P<0.0001) of Total Cholestrol (TC), Very Low Density Lipoprotein (VLDL) and Triglycerides (TG) were observed with the adjuvant therapy of Amlodipine and Atorvastatin. Pre-clinical studies with mice gave sufficient evidences regarding the effect of atorvastatin on muscles which may lead to myopathy. Combination therapy of Amlodipine and Atorvastatin safely reduces LDL, Total Cholesterol (TC) and VLDL. It may have a beneficial effect on cardiovascular outcomes especially in coronary artery disease. Possible effect of atorvastatin on skeletal muscles, leading to muscle weakness followed by myopathy needs the dose optimization of this combination therapy.

Keywords.Atorvastatin, amlodipine, lipid profile, myopathy, atheroscelosis